Multiple sclerosis (MS) is thought to be an immune-mediated disorder of the central nervous system that in most patients begins as an inflammatory relapsing-remitting disease.
1 Despite standard therapies, the majority of patients eventually enter a secondary-progressive phase for which no therapy has demonstrated efficacy. Fifty percent of patients are unable to continue employment by 10 years from diagnosis, require assistance to ambulate by 15 years, or are unable to walk by 25 years.
2 Despite an annual cost of approximately US $47 000 per patient
3,4 to treat MS, no therapy approved by the US Food and Drug Administration (FDA) has been demonstrated to significantly reverse neurological disability or improve quality of life.
5-11